Janani Ravikrishnan
Overview
Explore the profile of Janani Ravikrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ravikrishnan J, Diaz-Rohena D, Muhowski E, Mo X, Lai T, Misra S, et al.
Haematologica
. 2024 Aug;
110(1):78-91.
PMID: 39113656
Patients with chronic lymphocytic leukemia (CLL) respond well to initial treatment with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax. Upon relapse, they often retain sensitivity to BCL2 targeting, but durability...
2.
Muhowski E, Ravikrishnan J, Gordon B, Yu L, Misra S, Walker B, et al.
J Hematol Oncol
. 2022 Nov;
15(1):166.
PMID: 36380319
Inhibitors of B cell receptor (BCR) signaling such as the Bruton's tyrosine kinase (BTK) inhibitors are effective therapeutics for chronic lymphocytic leukemia (CLL). The first-in-class covalent BTK inhibitor, ibrutinib, produces...
3.
Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, et al.
Leukemia
. 2022 Nov;
37(2):326-338.
PMID: 36376377
Chronic lymphocytic leukemia (CLL) is effectively treated with targeted therapies including Bruton tyrosine kinase inhibitors and BCL2 antagonists. When these become ineffective, treatment options are limited. Positive transcription elongation factor...
4.
Lai T, Ozer H, Gasparini P, Nigita G, Distefano R, Yu L, et al.
Blood Adv
. 2022 Oct;
7(12):2897-2911.
PMID: 36287107
Chronic lymphocytic leukemia (CLL) is a quiescent B-cell malignancy that depends on transcriptional dysregulation for survival. The histone deacetylases are transcriptional regulators whose role within the regulatory chromatin and consequence...
5.
Yano M, Sharpe C, Lance J, Ravikrishnan J, Zapolnik K, Mo X, et al.
Blood Adv
. 2022 Apr;
6(20):5641-5654.
PMID: 35486482
Successes with anti-CD20 antibodies in chronic lymphocytic leukemia (CLL) and enhanced activity of Fc-engineered vs unmodified antibody therapy suggest a potentially impactful role for natural killer (NK) cells and other...
6.
Lai T, Mitchell S, Wu P, Orwick S, Liu C, Ravikrishnan J, et al.
Leuk Lymphoma
. 2019 Feb;
60(9):2308-2311.
PMID: 30773117
No abstract available.
7.
Wang S, Lee-Goldman A, Ravikrishnan J, Zheng L, Lin H
Biotechnol Bioeng
. 2017 Dec;
115(4):921-931.
PMID: 29278412
Perfusion processes typically require removal of a continuous or semi-continuous volume of cell culture in order to maintain a desired target cell density. For fast growing cell lines, the product...
8.
Wang S, Godfrey S, Ravikrishnan J, Lin H, Vogel J, Coffman J
J Biotechnol
. 2017 Feb;
246:52-60.
PMID: 28159614
Achievement of a robust and scalable cell retention device remains a challenge in perfusion systems. Of the two filtration systems commonly used, tangential flow filtration (TFF) systems often have an...